Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927909 | 1.00 | ESR1 (0.34) | ESR1ESR2CYP3A4CYP2C9ALDH1A1 | |
| Acetic Acid SCHEMBL3477522 | 0.87 | PLG (0.32) | — | |
| Acetic Acid SCHEMBL3477520 | 0.87 | PLG (0.32) | — | |
| SCHEMBL402037 | 0.86 | — | — | |
| SCHEMBL8792393 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL1316560 | 0.76 | ESR2 (0.46) | ESR1ESR2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL130642 | 0.76 | ESR2 (0.46) | ESR1ESR2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2267415 | 0.76 | ESR2 (0.46) | ESR1ESR2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL27912 | 0.76 | ESR2 (0.46) | ESR1ESR2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL4610 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158604-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-7989431-B2 | 4-{3-[6-Amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester; for inflammation, such as organ, tissue or cell transplantation, angioplasty (PCTA), inflammation following ischemia/reperfusion, or grafting | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-06-09 | — | — | US | disclosed |
| US-7875595-B2 | 5-[6-Amino-2-(2-hydroxy-adamantan-2-ylethynyl)-purin-9-yl]-3,4-dihydroxy-tetrahydro-furan-2-carboxylic acid cyclopropylamide for the treatment of inflammatory activity in mammalian tissue; A2A adenosine receptor agonist; autoimmune stimulation, allergic diseases, skin diseases, infectious diseases | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-7737127-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-7671191-B2 | Methods for preparing 2-alkynyladenosine derivatives | PGX HEALTH, LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671191-B2 | Methods for preparing 2-alkynyladenosine derivatives | PGX HEALTH, LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090298788-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION AND ADENOSINE THERAPEUTICS, L.L.C. | 2009-12-03 | — | — | US | disclosed |
| US-7605143-B2 | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-10-20 | — | — | US | disclosed |
| US-7576069-B2 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| US-20080177055-A1 | Methods for preparing 2-alkynyladenosine deriviatives | ADENOSINE THERAPEUTICS, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20080177055-A1 | Methods for preparing 2-alkynyladenosine deriviatives | ADENOSINE THERAPEUTICS, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-04 | — | — | US | disclosed |
| US-7214665-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| CN-1823084-A | Methods for preparing 2-alkynyladenosine derivatives | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-08-23 | — | — | CN | disclosed |
| US-20050033044-A1 | Methods for preparing 2-alkynyladenosine derivatives | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-02-10 | — | — | US | disclosed |
| EP-1079860-B1 | NICOTINE IMMUNOGEN | INDEPENDENT PHARMACEUTICA AB (SE) | 2004-10-27 | — | — | EP | disclosed |
| US-6656469-B1 | Treatment of nicotine dependence from tobacco products | INDEPENDENT PHARMACEUTICA AB (SE) | 2003-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298788-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | ESR1 831/4885ESR2 627/4885CYP3A4 1332/4885 |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | ESR1 2135/4885ESR2 1238/4885CYP3A4 874/4885 |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | ESR1 997/4885ESR2 632/4885CYP3A4 1117/4885 |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | ESR1 1745/4885ESR2 1007/4885CYP3A4 2287/4885 |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | ESR1 997/4885ESR2 632/4885CYP3A4 1117/4885 |
| US-20050033044-A1 | Methods for preparing 2-alkynyladenosine derivatives | ADORA2A, ADORA3, ADORA1 | ESR1 3339/4885ESR2 2924/4885CYP3A4 2154/4885 |
| US-20080177055-A1 | Methods for preparing 2-alkynyladenosine deriviatives | ADORA2A, ADORA3, ADORA1 | ESR1 3087/4885ESR2 2823/4885CYP3A4 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.